Paris Panayiotopoulos is a Senior Managing Director in the Blackstone Life Sciences group, having joined Blackstone as part of its acquisition of Clarus in December 2018.
Mr. Panayiotopoulos has over 20 years of biopharmaceutical operating experience, having served as President and CEO of Ariad Pharmaceuticals, President of the US, and Japan biopharmaceutical businesses of Merck, and as President of the Sereno Research and Development Institute. Prior to joining Merck KGaA, Mr. Panayiotopoulos was at Eli Lilly & Co. (NYSE: LLY)
Mr. Panayiotopoulos is Co-Chair of FerGene, a member of the Board of Directors of Anthos Therapeutics and on the Board of Advisors of the non-profit Life Science Cares.
He holds a combined BS in Chemistry and Management Studies from University College London and an MS from Cranfield Business School in the United Kingdom.